between long-term warfarin treatment and increased prevalence and extent of aortic valve and coronary calcifications, respectively. 12, 13 Potential mechanisms of MGP-mediated inhibition of VC represent inhibition of calcium-crystal growth, 14, 15 bone morphogenetic proteins, 16, 17 and transdifferentiation of VSMCs into an osteochondrogenic phenotype, respectively. 18 Here, we characterized the sequence of key events from initial VSMC apoptosis via vascular calcium loading toward alterations of functional cardiovascular parameters as a consequence of warfarin-induced VC in mice. This experimental animal model may serve as a valuable tool to test treatment strategies against VC applying transgenic approaches and to further decipher the functional network between the various calcification inhibitors and activators.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Calcium Measurement
Warfarin treatment provoked a dose-dependent increase in calcium deposition within the aortic and myocardial tissue, respectively, as shown by von Kossa staining (Figure 1) . Compared with the control group, the 0.3-and 3-mg/g warfarin with vitamin K1 groups exhibited significant increases of von Kossa-positive areas within the aortic wall (P<0.05 and P<0.01, respectively). The extent of calcified myocardial tissue in the 3-mg/g warfarin with vitamin K1 group was significantly increased compared with the control group (P<0.05 as calculated by the Kruskal-Wallis test). This was associated with a significant increase of calcium levels in aortic tissues and a nonsignificant increase in myocardial tissues as detected by cresolphthalein measurement (Figure 2A and 2B). After 7 weeks of treatment, the calcium deposition was further increased as detected by colorimetric detection from tissue extraction ( Figure 2D and 2E). Tissue calcium content concomitantly increased dose dependently in aorta and heart but nonsignificantly in lungs ( Figure 2C ). Using von Kossa staining, we failed to detect significantly positivestained areas in lungs ( Figure 2F and 2G). In kidneys, we did not detect substantial positive von Kossa staining at all (not shown). The additional treatment of 100 µg vitamin K2 with warfarin (3 mg/g) and vitamin K1 over 4 weeks resulted in significantly reduced calcium content in the aorta and myocardium compared with 3 mg/g warfarin with vitamin K1 alone ( Figures 1A and 2A ). In lungs, vitamin K2 addition led to significantly reduced calcium contents compared with 0.3 mg/g warfarin with vitamin K1 diet ( Figures 1 and 2 ).
Serum Chemistry and Total-ucMGP
Warfarin with vitamin K1-treated animals did not show any significant changes in serum levels of calcium, phosphorus, C-reactive protein, and blood urea nitrogen (not shown). Serum levels of total (t)-ucMGP revealed a dose-dependent increase in groups receiving 0.03 and 0.3 mg warfarin with vitamin K1 during 4 weeks, which was significant compared with the control group ( Figure 3A ). In the group with the highest warfarin concentration (3 mg/g warfarin with vitamin K1), t-ucMGP levels were lower compared with the group receiving 0.3 mg ( Figure 3A ). Addition of vitamin K2 to the 3-mg/g warfarin and vitamin K1 treatment did not result in a reduction of serum ucMGP levels compared with warfarin and K1 treatment alone ( Figure 3A ). Staining of the aortic wall for ucMGP and total MGP revealed an increase of ucMGP in warfarin-treated animals during 4 weeks compared with the control group, which is paralleled by a decrease of total MGP and total Gla residues ( Figure 3B -G).
Expression of Calcification-Related Genes
Vascular expression of the calcification-related genes MGP and osteopontin was altered in warfarin with vitamin K1-treated animals: MGP mRNA expression decreased significantly already with the lowest dose of warfarin (−76%) and was similarly reduced in all other dosages of warfarin ( Figure 4A ). Osteopontin mRNA expression was dose dependently increased, reaching statistical significance in the 3-mg warfarin with vitamin K1 group after 4 weeks of treatment (+206%) compared with control ( Figure 4B ). The expression of SM22α mRNA, a VSMC marker, was significantly reduced in the 0.03-mg/g warfarin with vitamin K1-treated mice (−68%) and was also similarly reduced in all other dosages of warfarin ( Figure 4C ). Treatment with vitamin K2 in addition to warfarin with vitamin K1 did not change SM22α or MGP expressions compared with warfarin with vitamin K1 treatment alone; for osteopontin, we detect a nonsignificant increase (+136%, P=0. 22) . Extending the treatment period to 7 weeks did not result in further significant alteration of the expression of the abovementioned genes ( Figure 4 ).
Evaluation of Cell Viability
Starting at 4 weeks of 3 mg/g warfarin with vitamin K1 treatment, cleaved caspase-3 and TUNEL (TdT-mediated dUTPbiotin nick end labeling) staining detected positive cells within the aortic vessel wall ( Figure 5A and 5B). In control animals, neither caspase-3 nor TUNEL staining revealed positive signals (not shown). The total cellularity was concomitantly significantly reduced as shown by decreased 4ʹ,6diamidino-2-phenylindole-positive nuclei within the aortic wall of 3 mg/g warfarin with vitamin K1-treated animals. The vascular cellularity was further reduced significantly when extending the treatment phase to 7 weeks compared with 4 weeks of treatment. Addition of vitamin K2 to warfarin and vitamin K1 during 4 weeks resulted in significantly higher cell numbers compared with 3 and 0.3 mg/g warfarin with vitamin K1 supplementation ( Figure 5C ).
Assessment of Echocardiographic Parameters
The peak velocity in the aorta, measured within the outflow tract, and the aortic valve-peak gradient increased significantly after 7 weeks of treatment with 3 mg warfarin with vitamin K1 (Figure 6A and 6B) . Similarly, the pulse-wave velocity (PWV) within the common carotid artery was increased after 4 (trend), and significantly after 7 weeks of treatment ( Figure 6C ). Pulse-wave velocity in the abdominal aorta was not significantly altered after 7 weeks of treatment (data not shown). Ejection fraction and diastolic function of the heart were not altered by warfarin administration at any time point (not shown).
Blood Pressure Measurements
We detected no difference between mice fed 3 mg/g warfarin with 1.5 mg/g vitamin K1 compared with control mice on systolic blood pressure levels after 4 (140±5 mm Hg and 130±10 mm Hg) and after 7 weeks (134±1 and 130±10 mm Hg, respectively). These values also did not differ from baseline values (138±11 mm Hg).
Discussion
We describe for the first time a model of warfarin-induced widespread cardiovascular damage in wild-type DBA/2 mice. This damage included VC with apoptosis in the vessel wall, reduced media cellularity, and impairment of functional cardiovascular parameters. Furthermore, this damage was blocked by treatment with vitamin K2. These effects seem to be mediated via blockade of MGP carboxylation. Price and coworkers created the first experimental model of warfarininduced VC in rats using a regimen of warfarin+vitamin K1, the latter to prevent lethal bleeding problems. 19 Carboxylated forms of MGP are found in intact vessel walls, and uncarboxylated forms colocalize with areas of VC. 20 This offers the possibility to modify the activity of MGP, which may influence the development of VC. Here, we demonstrate tissue deposition of calcium in the medial layer of the aortic wall and in myocardial and pulmonary tissue after treatment with warfarin. The calcium content increased in a warfarin dose-dependent manner. In lungs, the absolute calcium content was by far lower compared with the other tissues explaining the lack of von Kossa-positive staining. We attribute the chemical calcium detection to cartilaginous tissue because we did not detect overt von Kossa-positive staining in pulmonary vessel walls or alveoles. The procalcifying influence of warfarin on bronchi has been previously described in humans, 21 and MGP is known to be synthesized in chondrocytes as well. 22 Similarly, humans with mutations in the MGP gene, the so-called Keutel syndrome, display early diffuse pulmonary cartilage calcification, emphasizing the vitamin K-MGP-calcification axis within this organ system. 23, 24 Fatal bleeding complications occurred with low dosages of vitamin K1 (0.015 and 0.15 mg/g food) and were absent in high vitamin K1
(1.5 mg/g food) dose. Nevertheless, high dosages (ie, 1.5 mg/g food) did not protect mice against vascular calcification, which is in agreement with results obtained in rats. 19 Vitamin K2 coadministration reduced the development of calcification similar to a rat model of warfarin-induced calcification. 25 Warfarin dosages applied to mice in this experiment are far higher than those used in humans for inhibiting the coagulation cascade (eg, in the 3-mg/g group, daily intake was ≈10-15 mg per animal [25 g], the usual dose in humans is 5 mg per day/70 kg). This may account for the comparably rapid development of VC in these mice. Nevertheless, also in humans, there is growing evidence from observational studies, that long-term use of vitamin K inhibitors is associated with progression of coronary and VCs. [26] [27] [28] [29] To identify an alteration of the carboxylation status of MGP, we first stained for MGP in tissue sections of the aorta. We detected positive staining for the inactive form ucMGP in the medial vascular layer in warfarin-treated animals, whereas no staining was seen in control animals. This was paralleled by a reduction of total Gla residues and total MGP in warfarin-fed mice. Second, we assessed the levels of t-ucMGP in mouse sera. Compared with controls, we found a significant increase of t-ucMGP in low and medium dose levels of warfarin treatment Figure 6 . Warfarin administration during 4 and 7 weeks resulted in increased peak velocity (A), aortic valve (AV)-peak gradient (B) and an increased pulse-wave velocity in the common carotid artery (C). Concerning the peak velocity and AV-peak gradient, statistical significance was only reached after 7 weeks of treatment with 3 mg/g warfarin plus 1.5 mg/g vitamin K1. *P<0.05; **P<0.01. CCA indicates common carotid artery.
(0.03 and 0.3 mg/g) with vitamin K1 but a reduction in the highdose group compared with the medium group. This finding is in contrast to human data where warfarin treatment decreased t-ucMGP levels. 10 Nevertheless, our results are in line with the hypothesis that warfarin inhibits γ-carboxylation of MGP. In fact, the proportion of t-ucMGP to total MGP cannot be calculated because an assay of total MGP in mice is not available. The reduction of t-ucMGP in the highest warfarin dose might be explained by a transdifferentiation of VSMCs toward a non-MGP-producing osteoblastic phenotype or by increased apoptosis or nonapoptotic cell death within the vascular medial layer. Another explanation for the reduction in t-ucMGP in the high-warfarin group may be that the established colocalization of ucMGP with areas of calcification may resemble circulating ucMGP. T-ucMGP serum levels were not reduced after treatment with vitamin K2. Similar findings have been made in other vitamin K supplementation studies in rodents and possibly relate to the assay available. This is in contrast to human trials demonstrating a significant decrease of desphospho (dp)-ucMGP serum levels after vitamin K2 treatment. 30 For rodents, only an assay measuring t-ucMGP and not dp-ucMGP is available. The process of calcification is considered to be actively mediated 31 as indicated by a transdifferentiation of resident vascular cells like VSMCs. In the present study, a transdifferentiation of resident VSMCs in the vascular wall can be suggested by the reduction of the expression of VSMC-specific SM22α and the concomitant upregulation of osteopontin, which is a marker for osteoblast activity. This is in line with previous findings in the generation of VC. 32, 33 Aortic expression of the upstream regulatory gene cbfa1, which influences the expression of several osteoblastic genes, was also increased in the group of mice treated with 3 mg/g of warfarin but lacked significance (not shown). This further supports the hypothesis of a transdifferentiation of VSMCs towards an osteoblastic phenotype. Whether osteogenic progenitor cells invade into the calcified areas as recently proposed remain speculative in our model. 34 SM22α expression within the aortic wall decreased after 7 days of warfarin treatment, indicating that VSMC changes preceded detectable calcification. Vitamin K2 treatment together with warfarin and vitamin K1 supplementation did not significantly change the expression of abovementioned genes compared with warfarin and vitamin K1 alone. The reduction of SM22α expression in warfarin-and vitamin K1-treated mice may be related to cell loss within the vascular wall as well. Because apoptosis is known to facilitate the generation and progression of VC, 35 we tested for TUNEL-positive and caspase-3-positive staining in the vessel wall. Apoptosis may lead to calcification, and calcification stress may induce apoptosis. 35, 36 Here, apoptosis was only detectable after 4 weeks of warfarin and paralleled the occurrence of calcification in this experiment. Accordingly, we cannot answer the question whether calcification or apoptosis is the first finding in the development of VC. In control animals, we did not detect any positive TUNEL and caspase-3 staining. Vitamin K2 coadministration to warfarin with vitamin K1 resulted in preserved cell numbers in the aorta, which parallels the reduced calcification detected. Besides calcium deposition, apoptosis may also be induced by decreased carboxylation of the protein Gas6, which inhibits VSMC apoptosis. 37 Because specific antibodies against carboxylated Gas6 are lacking, we were not able to verify the latter hypothesis. Because gene expression of osteoblastic parameters was moderately increased, we cannot fully exclude that development of VC might also be independent of osteoblastic transdifferentiation at the time points evaluated here as mentioned recently. 15 Nevertheless, we speculate that we detected a start of transdifferentiation that might continue with longer duration of warfarin treatment and calcium accumulation in the aortic wall.
The assessment of functional cardiovascular parameters revealed indices of stenosis of the aortic outflow tract as mirrored by increased peak velocity in the aortic root (ascending aorta) and increased aortic valve gradient. This correlates with findings in humans in which the long-term use of warfarin leads to valvular calcification that in turn induces increased aortic valve gradients and velocities in the aorta. 26 Because we detected an increased PWV induced by warfarin in the carotid artery in mice, this needs to be addressed in human trials as well. An increased peripheral arterial stiffness is an independent risk factor for cardiac events and mortality. 38 This underlines the potential importance of local vitamin K availability in the vascular wall. We failed to detect significant differences in PWV in the abdominal aorta. This might be explained by lower degrees of calcification in the abdominal aorta than in the thoracic aorta. Indeed in the present study, the abdominal aorta was free from overt calcification (not shown). In humans, the assessment of PWV is performed between the carotid and femoral artery. Because of the lack of a comparable device for rodents, we could only measure PWV between shorter distances as described in the Methods section. These factors may account for the lack of difference in PWV in the abdominal aorta.
We have to point out that the described generation of VC in response to warfarin administration in mice is restricted to a genetic background of DBA/2 animals. The same protocol applied on C57BL/6 mice did not result in comparable generation of VC (data not shown). The DBA/2 mouse model is prone to VC possibly because of its diminished serum level of magnesium, 39, 40 which is considered as an antagonist of calcium effects. Only recently, warfarin has been proved to induce a vulnerable plaque phenotype in apolipoprotein E-deficient mice, expanding the influence of vitamin K antagonists from the vascular medial layer on intimal atherosclerotic lesions. 41 
